November 12th 2024
A 12-week regimen showed significant reductions in wrinkle severity and pigment improvement.
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Injectable Silicone Shows Promisefor Treatment of HIV-associated Facial Lipoatrophy
January 1st 2003Chicago -- Off-label experience using injectable silicone (Silikon 1000) in an investigational protocol indicates it is a highly effective and, thus far, very safe modality for treating facial lipoatrophy in HIV-infected patients, Derek H. Jones, M.D., said at the annual meeting of the American Society for Dermatologic Surgery.
Is Parental Consent Valid for Minor Children?
December 15th 2002Anew oral retinoid has been FDA cleared for the treatment of psoriasis. It has been shown to be safer than all previously available retinoids. Dr. Doe learned that this medication has been used safely in Europe for the prevention of acne in pre-adolescent teenagers. He has a large adolescent practice and is excited about using this medication on his young patients. Recognizing that the drug does not have FDA clearance for his intended use, he asks parents of prospective patients to sign a consent form allowing him to use this potentially miraculous drug on their children. Is the consent of the parent valid?
Silenced Silicone Needs FDA Signature
December 15th 2002A decade has passed since the FDA prohibited the use of injectable silicon for cosmetic purposes after complaints were made that leaking silicone breast implants caused a variety of autoimmune ailments, and that the migration of silicone in facial cosmetic use caused granulomas and permanent swelling.
New Applications Put Derm Surgery in Strong Position
November 15th 2002Zoe Diana Draelos, M.D., clinical associate professor, department of dermatology, Wake Forest University School of Medicine, and William P. Coleman III, M.D., editor, Journal of Dermatologic Surgery, discuss advances in dermatologic surgery.